Pancreatic Cancer Research

ResearcherNew York UniversityNo recent work listed

Johanna C. Bendell

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9426-5891; OpenAlex author ID A5028472820, A5088613691. Sources: ClinicalTrials.gov.

Their work

Papers
13 (first author 1, last author 1)
Trials
1
Grants
0
Labs led
0
Collaborators
63
Papers, trials and grants by year

2015: 2 papers, 1 trial · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers

Papers 13

  1. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1007/s10637-020-01000-6↗
  2. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Co-author DOI 10.1200/jco.20.02232↗
  3. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine i… Co-author DOI 10.1016/j.annonc.2019.09.004↗
  4. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel a… Co-author DOI 10.1016/j.annonc.2020.05.011↗
  5. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing… Co-author DOI 10.1186/s12885-020-07110-x↗
  6. Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I … Co-author DOI 10.1634/theoncologist.2020-0474↗
  7. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. First author DOI 10.1002/cam4.2425↗
  8. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase… Co-author DOI 10.1007/s10637-018-0580-2↗
  9. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing … Co-author DOI 10.1007/s10637-017-0473-9↗
  10. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreat… Co-author DOI 10.1634/theoncologist.2017-0024↗
  11. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAI… Last author DOI 10.1634/theoncologist.2017-0066↗
  12. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/meta… Co-author DOI 10.1093/annonc/mdu581↗
  13. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Ther… Co-author DOI 10.1200/jco.2015.61.4578↗

Trials 1

  1. TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Study chair NCT02574663↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zev A. Wainberg · 5 shared papers, 2015–2021 · strength 0.41
  2. Joel Randolph Hecht · 4 shared papers, 2017–2021 · strength 0.39
  3. Andrew H. Ko · 3 shared papers, 2017–2020 · strength 0.24
  4. Teresa Mercade Macarulla · 3 shared papers, 2017–2021 · strength 0.23
  5. J. Marc Pipas · 3 shared papers, 2015–2020 · strength 0.22
  6. Andrés Jesús Muñoz Martín · 2 shared papers, 2020–2021 · strength 0.21
  7. Sara Lonardi · 2 shared papers, 2020–2021 · strength 0.21
  8. Baek‐Yeol Ryoo · 2 shared papers, 2020–2021 · strength 0.21
  9. Manish R. Patel · 2 shared papers, 2020–2021 · strength 0.19
  10. Eileen Mary O'Reilly · 3 shared papers, 2015–2019 · strength 0.19
  11. Syed Farhan Zafar · 2 shared papers, 2020 · strength 0.18
  12. Fernando Rivera · 2 shared papers, 2020 · strength 0.18
  13. David J. Watkins · 2 shared papers, 2020 · strength 0.18
  14. Uwe Pelzer · 2 shared papers, 2020 · strength 0.18
  15. Hana Algül · 2 shared papers, 2020 · strength 0.18
  16. Madappa N. Kundranda · 2 shared papers, 2020 · strength 0.18
  17. Eric Van Cutsem · 2 shared papers, 2018–2021 · strength 0.18
  18. Vaibhav Sahai · 2 shared papers, 2018–2019 · strength 0.14
  19. Kenneth H. Yu · 2 shared papers, 2018–2019 · strength 0.14
  20. Ivelina Gueorguieva · 1 shared paper, 2021 · strength 0.11
  21. Joon Oh Park · 1 shared paper, 2021 · strength 0.11
  22. Richard Greil · 1 shared paper, 2021 · strength 0.11
  23. Charles D. Lopez · 1 shared paper, 2021 · strength 0.11
  24. Herbert I. Hurwitz · 2 shared papers, 2015–2018 · strength 0.11
  25. Myung Ah Lee · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.